Ms Mae Heng, 54, was appointed as an Independent Non-Executive Director on 4 May 2022 and was re-elected to the Board on 28 April 2023. She is also an independent board member of Rex International Investments Pte. Ltd., a subsidiary of the Group. Ms Heng has over 16 years of experience working at Ernst & Young Singapore. She is an Independent Non-Executive Director of Grand Venture Technology Limited, Chuan Hup Holdings Limited, HRnetGroup Limited, ISDN Holdings Limited and Progen Holdings Limited, and is the chairperson or a member of these companies’ various board committees. She is also Non-Independent Non-Executive Director of Ossia International Limited. Ms Heng holds directorships in her family-owned investment holding companies. She was a past board member of Novo Tellus Alpha Acquisition and Apex Healthcare Berhad. Ms Heng holds a Bachelor of Accountancy from the Nanyang Technological University. She is a Fellow Chartered Accountant with the Institute of Singapore Chartered Accountants and an ASEAN Chartered Professional Accountant. MAE HENG Independent Non-Executive Director Chairperson, Audit Committee Member, Remuneration and Nominating Committees Dr Mathias Lidgren, 43, was appointed as a Non-Independent Non-Executive Director on 4 May 2022 and was re-elected to the Board on 28 April 2023. He is also a board member of Masirah Oil Ltd, a subsidiary of the Group. Dr Mathias Lidgren represents the interests of Limea Ltd., the controlling shareholder of the Company. He had been a practising medical doctor since 2013 and has worked for the National Health Service (NHS), United Kingdom, the Hôpitaux Universitaires de Genève, Geneva, Switzerland, and the Sahlgrenska University Hospital, Gothenburg, Sweden. Up until 1 June 2024, he had been practising at Skane University Hospitals in Lund, Sweden, and was also a postdoctoral researcher in the Division of Molecular Medicine and Gene Therapy, Department of Laboratory Medicine in Lund University, Sweden. Dr Lidgren currently holds directorships in Propatria AB, Rotationsplast i Munka-Ljungby AB, Caithness Fastighets AB, Forvaltningsaktiebolaget Maple, Trolleholms Slott AB, and Captiosus AB; companies in Sweden involved in a range of businesses including real estate, manufacturing and medicine. He is the Chief Medical Officer of Moroxite T AB. Dr Lidgren holds a Doctor of Philosophy in Health Economics from the Karolinska Institutet, Sweden, a Master of Arts in Genetics, as well as a medical degree (MB BChir) from the University of Cambridge, United Kingdom and a Bachelor of Science in Business Administration (BSBA) from the International University of Monaco. His medical degree is recognised by the Commission des professions médicales, Switzerland and Socialstyrelsen, Sweden. He is licensed to practice medicine in the canton of Geneva, Switzerland and in Sweden. He is also a board-certified specialist in clinical genetics in Sweden. DR MATHIAS LIDGREN Non-Independent Non-Executive Director Member, Nominating Committee Rex International Holding Limited 1 1
RkJQdWJsaXNoZXIy NTM2MDQ5